Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
Fiche publication
Date publication
octobre 2019
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L
Lien Pubmed
Résumé
To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients.
Mots clés
CT-P13, Crohn’s disease, Patient education, Ulcerative colitis
Référence
Dig Liver Dis. 2019 Oct 21;: